Bionano Genomics (BNGO) vs Nephros (NEPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bionano Genomics (BNGO) has outperformed Nephros (NEPH) over the past year, losing 26.3% versus a loss of 36.2%. Over five years, NEPH leads with a -57.6% price change compared with -100.0% for BNGO. Nephros is the larger company by market cap ($35.7 million vs $17.2 million), about 2.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNGO | NEPH |
|---|---|---|
| Share price | $1.46 | $3.29 |
| Market cap | $17.19M | $35.73M |
| 1-day change | 0.00% | +2.81% |
| YTD return | -4.58% | -32.58% |
| 1-year return | -26.26% | -36.24% |
| 5-year return | -99.95% | -57.60% |
| P/E ratio (TTM) | — | 21.93 |
| Forward P/E | — | 15.67 |
| EPS (TTM) | $-3.02 | $0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.23 | $6.42 |
| 52-week low | $1.00 | $2.66 |
| Distance from 52-week high | -34.53% | -48.75% |
| Analyst consensus | none | none |
| Avg. price target upside | +242.47% | +89.97% |
| Average volume | 921.59K | 27.59K |
| Shares outstanding | 11.78M | 10.86M |
| Employees | 95 | 36 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Nephros is about 2.1 times larger than Bionano Genomics by market value ($35.73M vs $17.19M).
- The two companies sit in different sectors: Bionano Genomics in Industrials and Nephros in Health Care.
About Bionano Genomics
BNGO stock →Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants.
Industrials · Biotechnology: Laboratory Analytical Instruments · 95 employees
About Nephros
NEPH stock →Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities.
Health Care · Medical/Dental Instruments · 36 employees
BNGO vs NEPH FAQ
Which is bigger, Bionano Genomics or Nephros?
Nephros (NEPH) is larger, with a market capitalization of $35.73M compared with $17.19M for Bionano Genomics (BNGO).
Which stock has performed better over the past year, BNGO or NEPH?
BNGO returned -26.26% over the past 12 months, compared with -36.24% for NEPH (price return, excluding dividends). Past performance does not predict future results.
Are Bionano Genomics and Nephros in the same industry?
No. Bionano Genomics is in the Industrials sector, while Nephros is in Health Care.